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Background: Multiple myeloma (MM) is a low proliferative tumor of postgerminal center plasma cell (PC).
Centrosome amplification (CA) is supposed to be one of the mechanisms leading to chromosomal instability. Also,
CA is associated with deregulation of cell cycle, mitosis, DNA repair and proliferation. The aim of our study was to
evaluate the prognostic significance and possible role of CA in pathogenesis and analysis of mitotic genes as
mitotic disruption markers.
Design and methods: A total of 173 patients were evaluated for this study. CD138+ cells were separated by MACS.
Immunofluorescent labeling of centrin was used for evaluation of centrosome amplification in PCs. Interphase FISH
with cytoplasmic immunoglobulin light chain staining (cIg FISH) and qRT-PCR were performed on PCs.
Results: Based on the immunofluorescent staining results, all patients were divided into two groups: CA positive
(38.2%) and CA negative (61.8%). Among the newly diagnosed patients, worse overall survival was indicated in the
CA negative group (44/74) in comparison to the CA positive group (30/74) (P = 0.019).
Gene expression was significantly down-regulated in the CA positive group in comparison to CA negative in the
following genes: AURKB, PLK4, TUBG1 (P < 0.05). Gene expression was significantly down-regulated in newly
diagnosed in comparison to relapsed patients in the following genes: AURKA, AURKB, CCNB1, CCNB2, CETN2, HMMR,
PLK4, PCNT, and TACC3 (P < 0.05).
Conclusions: Our findings indicate better prognosis for CA positive newly diagnosed patients. Considering revealed
clinical and gene expression heterogeneity between CA negative and CA positive patients, there is a possibility to
characterize centrosome amplification as a notable event in multiple myeloma pathogenesis.
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Centrosomes are small organelles composed of two cylin-
drically shaped centrioles surrounded by pericentriolar
material in a normal mitotic cell. The centrosome function
is to direct mitotic bipolar spindles in a process that is
essential for accurate chromosome segregation during
mitosis [1,2]. After the initial assumption that amplified
centrosomes and abnormal mitotic arrangements might be* Correspondence: rom.hajek@seznam.cz
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enormous efforts have been undertaken to clarify the rele-
vance of centrosome amplification in carcinogenesis [3].
A vast number of solid and hematologic cancers harbor
centrosome amplification [3]; most of them are character-
ized by an inherent instability of their genome [4-8].
Analyses of human tumors have revealed a strong positive
correlation between centrosomal abnormalities and chro-
mosome number aberrations [9-15] and thereupon cen-
trosomal abnormalities are supposed to represent a poor
prognostic factor. However, correlative evidence does not
establish causality, and so far it has not been possible toentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Patients baseline characteristics
No. of patients 173
Follow-up median (min-max) [months] 27.5 (0.4-200.8)
Gender: males-females 37.5%-62.5%
Age median (range) [years] 64 (30–84)
ISS stage: I-II-III 30.3%-31.9%-37.8%
Durie-Salmon stage: I-II-III 6.5%-14.6%-78.9%
Durie-Salmon substage: A-B 79.8%-20.2%
Ig isotype: IgG-IgA-IgM-FLC-NonSecr. 62.3%-23.6%-0.9%-12.3%-0.9%
Light chains: kappa-lambda 66%-34%
No. of previous treatment lines
None (First line treatment) 79 (56.0%)
One 18 (12.8%)
Two 16 (11.3%)






Haemoglobin (g/l) 103.5 (73–157)
Thrombocytes (count x109) 193 (33–416)
Calcium (mmol/l) 2.3 (0.0-13.9)
Albumin (g/l) 38.3 (3.76-50.4)
Creatinine (umol/l) 101 (11–932)
β2-microglobulin (mg/l) 4.07 (1.1-42.6)
Lactate dehydrogenase (ukat/l) 3.39 (1.71-30.89)
C-reactive protein (mg/l) 4.15(0–174.3)
Monoclonal Ig (g/l) 31.05 (0–95.6)




13q14 deletion 75 (55.1%)
17p13 deletion 19 (13.6%)
Translocation t(4;14) 18 (14.3%)
1q21 gain 64 (46.7%)
Hyperdiploidy 55 (42.0%)
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frequent primary cause of aneuploidy.
Conversely, there is evidence that the centrosome
contributes to cell-cycle regulation and checkpoints
[4,16-20]. Both centrosome duplication and DNA rep-
lication are spatially and temporally tightly linked to
the cell cycle. The centrosome duplicates once every
cell cycle, which starts during the G1-S transition,
coincident with the onset of DNA replication. During
mitosis, duplicated centrosomes direct formation of
bipolar spindles, which is critical for accurate segregation
of chromosomes and cytokinesis [21,22].
MM is a low proliferative tumor of postgerminal cen-
ter PC. Normal PCs are arrested in the G1 phase of the
cell cycle. Malignant PCs have a proliferation rate that
increases from the early to the advanced stage of plasma
cell dyscrasia [23-25] and this proliferative feature is one
of the strongest adverse prognostic factors [25-29]. High
proliferation myeloma cell index estimates range from 1
to 3% [26,30], but approximately one third of PCs con-
tain centrosome amplification (CA) [31,32]. It appears to
be plausible that deregulation of the cell cycle earlier
during MM pathogenesis leads to accumulation of cen-
trosomes and their succession to aberrant PC. Aborted
PC mitoses might also contribute to causing numerical
centrosome aberrations in MM [4]. In connection to the
low amount of complete mitosis, CA possibly does not
contribute much to accumulation of chromosome
instability (CIN) in new cell generations.
Previously published data about clinical implication of
CA was reported based on the so-called centosome
index (CI) [31]. In fact, CI is surrogate gene expression–
based index calculated by adding the normalized
expression value of centrin, pericentrin and γ-tubulin
genes. It is established that centrosome index correlates
with CA, poor prognostic features as well as very short
survival [31,33].
Although clinical implication of centrosome amplifica-
tion in MM is still unclear, it is obvious that the role of
CA as well as CA formation in MM differ from other
malignancies. We anticipate that such differences are
based on specificity of malignant transformation in MM
genesis. The aim of our study was to evaluate prognostic
significance and possible role of centrosome amplifica-
tion in pathogenesis and analysis of mitotic genes as
mitotic disruption markers.
Design and methods
Patients & sample preparation
A total of 173 MM patients enrolled in University
Hospital Brno, Czech Republic, University Hospital
Olomouc, Czech Republic and University Hospital
Bratislava, Slovakia, were included in this study. The
patients’ baseline characteristics are summarized inTable 1. The study was approved by the Ethical
Committee of the Faculty of Medicine, Masaryk
University (chairman: Josef Kure, PhD; ref number:
14/2009), and the study was conducted according to
the Helsinki declaration. The bone marrow of
patients was obtained during routine diagnostic
procedure. Plasma cells in mononuclear cell fraction
were enriched by anti-CD138+ immunomagnetic
beads and sorted using AutoMACS Pro (Miltenyi
Biotec). Purity of CD138+ fraction was measured by
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plasma cells were provided for total RNA isolation.
Centrin immunofluorescent labeling and image analysis
PCs visualization with immunoglobulin light chain stain-
ing (cIg) and immunofluorescent labeling of centrin as
an integral centrosome protein for centrosome copy num-
ber determination, was performed as described previously
[32,34]. Brief workflow was as follows:
Cytospin slides for immunolabeling detection of CA in
PCs are prepared as follows: approximately 100,000
BMMC are placed on a slide and air dried for 24 hrs at
room temperature. Then, PCs are fixed in ice-cold
methanol for 5 min at room temperature. Cytoplasmic
membrane permeabilization is done by Triton X-100
0.2% (Affymetrix/USB, UK) for 1 minute at 37°C. After
that, slides are placed in PBS for 10 min using gentle
agitation. To prevent non-specific binding, blocking
buffer (PBS with 10% normal goat serum – Santa Cruz
Biotechnology, Inc., CA, USA) is added to each slide and
incubated for 20 min in the wet chamber at 37°C. After
incubation, the blocking buffer is poured off by gentle
agitation during 10 min. After that, 20 μl of diluted
(3 : 1000) primary antibody (Centrin 1/2 rabbit poly-
clonal antibody Santa Cruz Biotechnology, Inc.) is
applied to each slide. The slides are incubated for
1 hr in the wet chamber at 37°C. To wash out un-
specific antibody binding, slides are washed 3 times
with phosphate buffered saline (PBS) for 5 min each
using gentle agitation. The secondary goat anti-rabbit
IgG antibody (1.5 : 1000) is applied (Santa Cruz
Biotechnology, Inc.) and incubated under the same
conditions for 45 min. Another step of washing is
done again 3 times (PBS for 5 min, light-protected).
Further immunolabeling on cytospin slides is done,Figure 1 Different pattern of centrin staining. The isotypic PCs were ide
(cIg, blue), and centrin was stained with anticentrin1/2 conjugated with TR
microscope with Vosskuhler 1300D digital camera and LUCIA-KARYO/FISH/
Republic). (For interpretation of the references to color in this figure (A) Tw
centrosome. (B) Abnormal PCs with centrosome amplification (>4 fluoresceusing immunoglobulin light chain staining, according
to the procedure described previously [7]. A cover slip is
applied on all slides using mounting medium antifade
without propidium iodide (PI) for PC visualization. One
hundred cells were scored per each slide. Up to four
centrin signals (representing four centrioles of two centro-
somes) can be present in a normal cell depending on the
phase of cell cycle. Samples with more than 10% of PCs
with >4 signals of centrin were considered as CA-positive
(Figure 1) [31,32,34].
Fluorescence in situ hybridization (FISH)
FISH was performed as a part of routine diagnostic
procedure according to the previously described
protocol [35]. The following aberrations were studied:
1q21 gain, 13q14 deletion, 17p13 deletion and trans-
location t(4;14). The following probes were used: LSI
13q14 (RB1) Spectrum Orange Probe, LSI p53
(17p13.1) Spectrum Orange Probe, LSI IGH/FGFR3
Dual Color Probe, LSI 13q34 Spectrum Green and
CEP 17 Spectrum Green reference probes (Abbott
Vysis, Prague, Czech Republic). Gain 1q21 was
detected using BAC DNA RP11-205 M9 probe.
Hyperdiploidy status was determined with commer-
cial probes mapping to chromosome 5 (LSI D5S23/
D5S721), 9 (CEP9) and 15 (CEP15) (Abbott Molecu-
lar, Des Plaines, IL, USA). Fifty to one hundred
plasma cells were evaluated for each sample. We
used cut-off values recommended by the European
Myeloma Network [15]. An Olympus BX 61 (Olympus,
Prague, Czech Republic) fluorescence microscope and a
Vosskuhler 1300D CCD camera were used for image
acquisition. Image analysis was carried out using LUCIA-
KARYO/FISH software (Laboratory Imaging, Prague,
Czech Republic).ntified by cytoplasmic or light chain antibody conjugated with AMCA
. The cells were visualized using Olympus BX-61 fluorescent
CGH digital analysis system (Laboratory Imaging, s.r.o, Prague, Czech
o signals – cells with 1–4 signals were considered to have normal
nce signals of centrin).
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Total RNA was isolated using QIAGEN RNeasy Mini
Kit. RNA isolation and purification were described
previously [36]. RNA was isolated from either fresh
or frozen material according to the manufacturer’s
protocol. For frozen material, the cells were left in
RLT buffer and β-mercaptoethanol for 1 hr at room
temperature with occasional vortexing based on tech-
nical support information of the manufacturer to
improve RNA purity.
Total RNA with purity ratio 260/280 >1.7 and integrity
(RIN) >7.5 (as measured by Agilent 2010 Bionalyzer)
was used for further analyses.
Quantitative real-time PCR (qRT-PCR)
Quantitative RT-PCR was focused on a chosen list of
genes, according to their role in normal centrosome
duplication process. qRT-PCR was performed using the
Applied Biosystems platform. Input of 100 ng of
high-quality total RNA was reverse transcribed using
High Capacity cDNA Reverse Transription Kit and
preamplified with TaqMan PreAmp MasterMix Kit
(Applied Biosystems, Foster City, CA). Expression of
each gene was evaluated in a duplex reaction by
TaqMan Gene Expression Assays and GAPDH as an
internal control on 7500 Real Time PCR System.
Relative fold change of expression for each gene was
calculated using the ΔΔCt method.
Statistical analysis
For continuous variables, nonparametric Kruskal-Wallis
or Mann–Whitney tests were used. For discrete vari-
ables, chi-squared test for independence of Fisher’s exact
test was used. The overall survival (OS) calculated from
the date of diagnosis and survival rates were estimated
using the Kaplan-Meier method. Differences of survival
among subgroups of patients were compared using theTable 2 Comparison of levels of biochemical parameters in C
Biochemical parameter CA negative
Hemoglobin (g/l) 99.75 (73–157)
Thrombocytes (count x109) 199.5 (45–391)
Calcium (mmol/l) 2.41 (1.95-3.59)
Albumin (g/l) 35.85 (21.1-50.4)
Creatinine (umol/l) 115 (59–932)
β2-microglobulin (mg/l) 5.43 (1.1-42.6)
Lactate dehydrogenase (ukat/l) 3.17 (1.77-16.49)
C-reactive protein (mg/l) 5.2 (0.0-174.3)
Monoclonal Ig (g/l) 32.4 (0.0-83)
PC infiltration of bone marrow (%) 44.4 (2.2-93.6)
All values presented as median (range).log-rank test. Cox proportional hazards models were
used to assess the association of several prognostic
factors with OS. P-values below 0.05 were considered
statistically significant.
Results
Characteristics and clinical outcome of patients
All patients involved in this study were stratified into
two subgroups (CA negative and CA positive) based on
centrin immunofluorescent staining results. Frequencies
of patients among subgroups were as follows: 38.2%
(66/173) in CA positive, 61.8% (107/173) in CA negative,
respectively.
There were no significant differences regarding the
presence/absence of selected chromosomal aberrations
including 13q14 deletion, 17p13 deletion, translocation t
(4;14), translocation t(14;16), 1q21 gain and hyper-
diploidy detected by FISH in these two subgroups
(Additional file 1: Table S2). Also, CA-based patient sub-
groups have similar distribution of Durie-Salmon staging
(P = 0.29) as well as ISS staging (P = 0.46). Comparison
of biochemical parameters showed significant differences
in hemoglobin and creatinine level between CA positive
and CA negative groups (Table 2). These differences are
probably associated with the frequency of renal failure in
CA positive (6/27) and CA negative group (15/44).
To determine the prognostic impact of patients in
defined subgroups, we compared their overall survival.
Although statistical significance was not reached for the
whole studied cohort (data not shown), significant diffe-
rences were observed in newly diagnosed patients
(74/139). Worse OS was indicated in CA negative patients
(44/74) in comparison with CA positive patients (30/74)
(P = 0.019) (Figure 2). None of the patients from the
subgroup with prognostic implication of CA (newly
diagnosed group) had transplants before sample with-












Figure 2 Overall survival of CA groups of newly diagnosed MM patients. Kaplan-Meier curves for OS of newly diagnosed MM patients
(n = 74). CA positive patients (n = 30) had significantly better survival when compared to CA negative patients (n = 44) subgroups (P = 0.019).
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of transplantation frequency between CA positive/
negative groups showed an absence of significant diffe-
rence (P > 0.05). Univariate Cox proportional hazards
survival model with one explanatory variable showed
worse prognosis for CA negative group (HR 0.236 [HR95%
CI: 0.068; 0.818]; P = 0.023). All disease-related deaths
occurred in two years after the diagnosis and were signifi-
cantly higher in the CA negative group (7/44) than in the
CA positive (0/30) group of patients (P = 0.037).
To further characterize the prognostic significance of
CA multivariate Cox proportional hazards survival
model was used (Table 3). The variables in the multi-
variate model were the only variables which remained
statistically significant when potential predictors were
combined together as well as CA which was forced into
the model (Additional file 2: Table S1). The results suggest
a trend of CA importance for survival of patients in spiteTable 3 Multivariate Cox proportional hazards survival
model containing centrosome amplification and other
significant variables
HR HR 95% CI P
CA negative 1.000
CA positive 0.221 (0.049; 1.008) 0.051
Age at time of diagnosis 1.088 (1.023; 1.158) 0.007
LDH 1.249 (1.100; 1.419) 0.001
Event of interest is death (‘related to disease’ or ‘other death reason’).of its border statistical significance even when combined
with other predictors (Table 3).
Expression level of selected genes in different subgroups
of patients and gene expression-based assessment of
proliferation
In total, 10 genes (AURKA, AURKB, CCNB1, CCNB2,
HMMR, PLK4, PCNT, TUBG1, TACC3, and CDK2) asso-
ciated with centrosome structure/function were selected
for qRT-PCR analyses. We found significant differences
in relative quantification coefficient R of AURKB, PLK4
and TUBG1 genes that were down-regulated in the CA
positive group in comparison with CA negative patients
(p < 0.05) (Figure 3).
Analyses of gene expression in newly diagnosed and
relapsed patients showed significant changes of the
following genes: AURKA, AURKB, CCNB1, CCNB2,
CETN2, HMMR, PLK4, PCNT, and TACC3; these
were up-regulated in relapsed patients (p < 0.05)
(Figure 4).
Expression of some genes connected with centro-
some formation and function (AURKA, AURKB,
CETN2, and PLK4) was significantly different between
hyperdiploid and non-hyperdiploid myeloma patients
(Figure 5).
Discussion
Recent studies revealed the presence of CA in plasma
cells in all stages of monoclonal gammopathies [31].
However, strong causality between CA and chromosome
Figure 3 Gene expressions in CA groups of newly diagnosed MM patients. The expression levels of selected genes were compared in CA
positive and CA negative groups of newly diagnosed MM patients. Significant differences (P < 0.05) in relative quantification coefficient R (abscissa
axis) are marked with an asterisk.
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shown; so far, the role of CA in MM pathogenesis is
still unclear. Moreover, there is not enough infor-
mation regarding the mechanism of cell cycle
dysregulation in MM pathogenesis. The primary
objective of this work was to evaluate the prognostic
significance and possible role of centrosome amplifi-
cation in pathogenesis and analysis of mitotic genes
as mitotic disruption markers.
In this study, we have shown that better OS was
indicated for CA positive patients. In addition, CA
as a prognostic factor was relevant for disease relatedFigure 4 Gene expressions in newly diagnosed and relapsed MM pat
newly diagnosed and relapsed MM patients. Significant differences (P < 0.0
with an asterisk.death cases that occurred within two years after the
diagnosis.
At first sight our results contradict previously
published findings. Chng et al. have shown that gene
expression-based centrosome index (calculated by
adding the normalized expression of three major
centrosome structural proteins and components of
the pericentriolar material) is associated with poor
prognostic genetic subtypes and portends short
survival [31,33]. On the one hand, this study has not
found any association between the presence of CA
(immunofluoriscent staining of centrin) and overallients. The expression levels of selected genes were compared in
5) in relative quantification coefficient R (abscissa axis) are marked
Figure 5 Gene expressions in hyperdiploid and non-hyperploid MM patients. The expression levels of selected genes were compared in
hyperdiploid and non-hyperploid MM patients. Significant differences (P < 0.05) in relative quantification coefficient R (abscissa axis) are marked
with an asterisk.
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tion can be caused by different treatment protocols
used in our studies. This is determined by the year
the research was conducted in. In the study of Chng
and colleagues, treatment regimens were based
mainly on old generation drugs (dexamethasone-based
treatment or melphalan and prednisolone treatment);
in the current study new treatment protocols were
used (thalidomid-, bortezomib- or lenalidomide-based
protocols). There is a possibility that CA-positive
MM subclone is more sensitive to new agents but
this anticipation needs to be proved in future detailed
studies (personal communication with prof. Chng).
We suggest that CA presence can be explained as
heritage from myeloma progenitors and their mitotic
checkpoint alteration, whereas gene expression changes
can occur in numerous physiological and/or pathological
processes. This statement is in concordance with other
findings in expression changes of genes associated with
centrosome structure/function. Expression of the above
mentioned genes was different not only in CA
subgroups or related to ploid category but it was also
different in newly diagnosed and relapsed patients.
A cancer cell may be derived from a mature progenitor
cell that has acquired stem cell properties, i.e. self-renewal
and immortality. In this case, the oncogenic event(s)
enable(s) the cell(s) to self-renew. It is possible that
some events, such as oncogenic targeting of the
centrosome, trigger proliferation, survival and self-renewal
at the same time and can target indifferently committed
progenitors [37].Although most of the multipolar divisions that
occur in tumors probably reflect non-productive
events, an occasional division might give rise to pro-
geny with a genetic constitution that favors survival
in a changing physiological environment. Selective
pressure might arise, for instance, through increasing
hypoxia or nutritional deprivation in a growing tumor
mass, or through the presence of a chemotherapeutic
drug [4]. Damage of G2/M and G1/S checkpoints
finally provides the proliferating clone with a more
aggressive armament, which includes growth factor
and stromal independence, absence of response to
differentiation signals and absence of polarity. It was
shown by Sato et al. that centrosome overduplication
may be a critical event leading to mitotic failure and
subsequent cell death following crucial damaging
influence and that it represents a mechanism defen-
ding the organism from abnormal cell accumulation
[38]. Thus, our findings indicating better prognosis
for CA positive patients are in concordance with the
fact that mitotic aberrations associated with numerical
and functional abnormalities of centrosomes trigger
spindle checkpoints, leading to mitotic catastrophe
and cell death [39]. Afterwards, because of clone
selection, CA lost their positive clinical implication in
cohorts of relapsed patients.
Obviously, our findings need to be confirmed and
validated on a larger external cohort of patients. We
believe that future investigation of centrosome amplifi-
cation will help to refine the broad prognoses offered by
current established systems and even sub-stratify them.
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